Aclaris Therapeutics
ACRS
84 hedge funds and large institutions have $78M invested in Aclaris Therapeutics in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 22 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 27
5.5% less ownership
Funds ownership: 91.79% → 86.29% (-5.5%)
12% less funds holding
Funds holding: 95 → 84 (-11)
41% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 22
66% less capital invested
Capital invested by funds: $227M → $78M (-$149M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $414K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$5.91M |
| 2 |
Man Group
London,
United Kingdom
|
+$4.76M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.82M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$12.2M |
| 2 |
DM
Deerfield Management
New York
|
-$10.4M |
| 3 |
D.E. Shaw & Co
New York
|
-$6.45M |
| 4 |
Axa
Paris,
France
|
-$1.82M |
| 5 |
CIA
Capital Impact Advisors
Boston,
Massachusetts
|
-$1.39M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
SEI Investments
Oaks,
Pennsylvania
| – | -$18K | -3,277 | Closed |
|
102
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$11K | -1,818 | Closed |
|
|
TRCT
103
Tower Research Capital (TRC)
New York
| – | -$6K | -946 | Closed |
|
ACRS Hedge Fund Activity: Q2 2019 in Review
84 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2019, worth a combined $78M — down 66% from $227M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ACRS and 13 opened new positions — a net loss of 9 holders — while 27 trimmed existing stakes and 33 added.
The largest buyer was Endurant Capital Management, adding an estimated $5.91M. The largest seller was Broadfin Capital, exiting entirely with an estimated $12.2M sold.
- 84 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2019, down from 95 in Q1 2019.
- Funds reported $78M of Aclaris Therapeutics stock for Q2 2019, down 66% quarter-over-quarter.
- 13 funds opened new Aclaris Therapeutics positions in Q2 2019 and 22 closed out, a net change of -9 holders.
- The largest Aclaris Therapeutics buyer in Q2 2019 was Endurant Capital Management, an estimated $5.91M added.
- The largest Aclaris Therapeutics seller in Q2 2019 was Broadfin Capital, an estimated $12.2M sold.
Based on aggregated 13F filings for Q2 2019.